ASTRO 2025: Advancing the Frontier of Personalized Cancer Care.

During the 67th annual meeting of the American Society for Radiation Oncology Annual Meeting (ASTRO), held September 27 – October 1, 2025 in the Moscone Center, San Francisco, CA, Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, presented study results demonstrating the company’s vision to advance the frontier of personalized cancer care.

The presented data included the first validation of the ArteraAI Prostate Test in an Asian patient cohort; the rapid development and validation of its multimodal artificial intelligence (MMAI) biomarker for head and neck cancer; and emerging data demonstrating how MMAI biomarkers offer distinct yet complementary insights to genomic classifiers.

• A prognostic multimodal artificial intelligence (MMAI) model (Abstract 1117)

Presented in collaboration with the National Cancer Centre Singapore, this study marks the first validation of the digital pathology-based MMAI prognostic model (ArteraAI Prostate Test) in an Asian prostate cancer population.

The test was originally developed using biopsy image and clinical data from North American (NA) phase 3 clinical trials. Although the model has been shown to accurately predict outcomes in mostly Caucasian and African-American men with PCa, data is lacking on its performance in Asian patients, particularly in non-NA settings. Hemce, the researchers set out to validate the prognostic MMAI model in an Asian PCa cohort from Singapore.

The test results demonstrated that the test was an independent prognostic tool in Asian men with prostate cancer, confirming its consistent, bias-free performance across diverse populations and clinical settings.

This validation builds on data presented at the 2024 ASCO Annual Meeting, which demonstrated predictive performance in African American men, another historically underrepresented group in biomarker research.

• A Digital Pathology-Based, Multimodal Artificial Intelligence (MMAI) in  Head and Neck Cancer (Abstract 177) 

Head and neck cancer is the seventh most common cancer globally, with more than 1.1 million new cases annually, yet there are currently no commercial risk classifiers available. In addition, prognostication of clinical outcomes of head and neck cancers (HNC) remains challenging and complicated, This is understood to be caused by the heterogeneity of these cancers. The researchers of this study hypothesized that a digital pathology (DP)-based MMAI approach to biomarker development could provide a quantitative prognostic classifier.

Artera developed and validated a new MMAI biomarker for locoregionally advanced head and neck cancer independent of stage and HPV status, in just five months.

The biomarker was prognostic for survival and disease progression, regardless of stage or HPV status, and validated in patients treated with either definitive radiation or surgery.

The outcomes of this study, performed in collaboration with NRG Oncology, suggests that DP images contain important prognostic information beyond those captured by known clinical features.

Artera’s MMAI biomarker fills this critical unmet need.

Breadth of data
“The breadth of data we’re presenting at ASTRO 2025 highlights the scalability and global potential of Artera’s platform,” noted Andre Esteva, CEO and Co-founder of Artera.

“We’ve now demonstrated the ability to extend our core technology across new cancer types and patient demographics — rapidly, and with clinical rigor. These moments reinforce our position as a category-defining precision medicine company, and reflect our strategy to build a scalable platform with broad clinical and commercial utility,” Esteva added.

In addition to these studies, two more abstracts were presented that further validate the distinct and complementary insights Artera’s MMAI biomarkers can provide alongside existing genomic classifiers, supporting more nuanced, data-driven treatment decisions. These included

• Oral Presentation: Genomic classifier and multimodal AI biomarker in localized prostate cancer: Two sides of the same coin. Abstract Number: Abstract 360 [1]
• Poster Presentation: Evaluating the Correlation Between Genomic Classifier and Digital Pathology-Based Multi-Modal AI Biomarkers in Localized Prostate Cancer. Abstract Number: Abstract 3121

Reference
Parker CTAP, Liu VYT, Mendes L, Grist E, Yamashita R, Croucher DC, Sachdeva A, Murphy L, Huang HC, Jones RJ, Gillessen S, Parker CC, Berney D, Tran PT, Spratt DE, Parmar MKB, Clarke NW, Brown LC, Attard G.Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE. Journal of Clinical Oncology 2025 43:16_suppl, 5001-5001

Featured image: Golden Gate Bridge view at foggy morning, San Francisco, California, USA. Photo courtesy © 2016 – 2025 Fotolia/Adobe. Used with permission.

DOI